UC Irvine Study Reveals Serious Infection Risks with Targeted Cancer Therapies

A major real-world Peer-reviewed study led by UC Irvine pharmacy researchers has identified serious blood-related side effects, including dangerously low white blood cell counts (severe neutropenia) and related complications like hospitalization, associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. The study, published in the journal Cancers, analyzed data from 3,511 patients and highlights the need for closer monitoring and supportive care as these therapies become more widely used.